Table 1.

Responses and adverse events

Study/report	Timing of administration of rituximab	Response	Adverse events
Shimada et al. [3]	1st: 23 cases	NA	10 of 23 cases developed infusion reactions; hypoxia was observed in 3 of the 10 cases and Grade 3 severe hypoxia in 1 case
Shimada et al. [3]	2nd: 25 cases	NA	4 of 25 cases developed infusion reactions
Ohkubo et al. [23]	1st	CR	None
Imahashi et al. [15]	1st	CR	NA
Aoyama et al. [14]	1st	NC	Grade 3 sick sinus syndrome
Kaku et al. [16]	1st	CR	None
Okachi et al. [24]	1st: 2 cases	CR	NA
Wakamatsu et al. [34]	1st	CR	NA
Shimizu et al. [27]	1st: 5 cases	CR	NA
Takahashi et al. [31]	1st	CR	NA
Tanikawa et al. [33]	1st	NC	NA
Sawa et al. [26]	1st	CR	NA
Watanabe et al. [35]	1st	CR	NA
Sakurai et al. [25]	1st	CR	NA
Takizawa et al. [32]	1st	CR	NA
Nakano et al. [22]	1st	NC	NA
Kotake et al. [21]	2nd	CR	NA
Shinoda et al. [28]	2nd	CR	NA
Shimada et al. [1]	2nd	CR	None
Ishizuka et al. [17]	2nd	CR	NA
Iwagami et al. [18]	2nd	CR	NA
Kashizaki et al. [19]	2nd	CR	Unspecified*
Kobayashi et al. [20]	2nd	PR	NA
Sakurai et al. [25]	2nd	CR	None
Suzuki et al. [29]	2nd	CR	NA
Tadokoro et al. [30]	2nd	CR	NA
Our other case	1st	CR	Grade 1 fever, chills, hypoxia
Present case	1st	NA	Death

NA, not applicable; CR, complete response; NC, no change; PR, partial response. *In this case, rituximab administration was attempted during the first course, but an infusion reaction was observed and the rituximab injection was discontinued. However, rituximab was administered according to protocol during the second course.